First and foremost, the non small cell lung cancer market is a massive one. In fact, it is expected that the market for the treatment of this cancer will grow to be worth more than $10.5 billion annually by 2025.
Tapping into such a large market opportunity would likely lead to a significant increase in revenue.
Moreover, this is a late-stage clinical trial. Pivotal Phase 3 clinical trials are the final trial that takes place before submitting applications to regulatory authorities.
With positive data in a Phase 3 trial, the company is likely to move toward the submission of this new treatment option with the FDA and other regulatory bodies around the world.
Finally, during the trial, BMY put its treatment head to head with the current standard of care therapy. With positive results in this clinical trial, the data suggests that the company’s combination therapy could take a large share of the market due to significantly improved outcomes.
Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!
Don’t Miss The Next Big Story!
Join our free mailing list below to receive real-time news alets!